Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging
Executive Summary
FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death